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Abstract
Objective To determine the accuracy of testing for human papillomavirus
(HPV) DNA in urine in detecting cervical HPV in sexually active women.
Design Systematic review and meta-analysis.
Data sources Searches of electronic databases from inception until
December 2013, checks of reference lists, manual searches of recent
issues of relevant journals, and contact with experts.
Eligibility criteria Test accuracy studies in sexually active women that
compared detection of urine HPV DNA with detection of cervical HPV
DNA.
Data extraction and synthesis Data relating to patient characteristics,
study context, risk of bias, and test accuracy. 2×2 tables were constructed
and synthesised by bivariate mixed effects meta-analysis.
Results 16 articles reporting on 14 studies (1443 women) were eligible
for meta-analysis. Most used commercial polymerase chain reaction
methods on first void urine samples. Urine detection of any HPV had a
pooled sensitivity of 87% (95% confidence interval 78% to 92%) and
specificity of 94% (95% confidence interval 82% to 98%). Urine detection
of high risk HPV had a pooled sensitivity of 77% (68% to 84%) and
specificity of 88% (58% to 97%). Urine detection of HPV 16 and 18 had
a pooled sensitivity of 73% (56% to 86%) and specificity of 98% (91%
to 100%). Metaregression revealed an increase in sensitivity when urine
samples were collected as first void compared with random or midstream
(P=0.004).
Limitations The major limitations of this review are the lack of a strictly
uniform method for the detection of HPV in urine and the variation in
accuracy between individual studies.
Conclusions Testing urine for HPV seems to have good accuracy for
the detection of cervical HPV, and testing first void urine samples is
more accurate than random or midstream sampling. When cervical HPV
detection is considered difficult in particular subgroups, urine testing
should be regarded as an acceptable alternative.
Introduction
Human papillomavirus (HPV) is one of the commonest sexually
transmitted infections. Up to 80% of sexually active women are
infected at some point in their lives and 10-20% develop
persistent infection.1 Infection with specific strains of HPV has
been associated with the development of cervical cancer,2 a
preventable and treatable disease for which routine screening
using a cervical cytology based method is employed to detect
precancerous cervical intraepithelial neoplasia (CIN). Despite
screening, cervical cancer is still the most commonmalignancy
in women aged less than 35, and there has been a downward
trend in coverage of screening in this population.3 4 This may
partly be because the current screening by cervical cytology
sampling is invasive, is time consuming, and requires a clinician.
The detection of HPV in the cervix is being piloted as a new
method of cervical cancer screening and is recommended for
secondary prevention.5 This is based on four randomised
controlled trials and a pooled analysis of these, which showed
that HPV detection is more protective against grade 3 CIN and
invasive cervical cancer compared with current screening
methods.6-9 However, cervical HPV detection shares many of
the problems of current cytology based screening programmes.
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It is still invasive and time consuming and is unlikely to resolve
the problem of poor screening uptake. Detection of HPV in
urine would offer a more accessible and acceptable method.10
It could also be used for post-vaccination HPV surveillance
programmes, where pelvic examination is not practical.
Published reviews assessing detection of urine HPV conclude
that urine sampling is a feasible alternative to cervical sampling.
However, they do not include a meta-analysis of test
accuracy.11 12We conducted a systematic review and
meta-analysis to determine the accuracy of detection of HPV
in urine compared with the cervix in sexually active women.
Methods
A prospective protocol was registered on PROSPERO
(identification number CRD42013006928).13 This review was
performed using recommended methods and reported in
accordance with the preferred reporting items for systematic
reviews and meta-analyses (PRISMA) statement.14 15
Search strategy
We searched several electronic sources from inception to
December 2013: Medline, Embase, the Cochrane Library, Web
of Science, BIOSIS, DARE, and SIGLE. MeSH and free text
combinations using Boolean logic of the following search terms
were used: urin*, self, home, test*, detect*, screen*, diagnos*,
DNA, deoxyribonucleic acid, polymerase chain reaction, NAAT,
NAT, nucleic acid test, nucleic acid amplification test, HPV,
human papillomavir*, cervical cancer, and cervical pre-cancer.
We manually searched recent issues of relevant publications
and the reference lists of included texts and relevant articles.
Experts were contacted for additional studies and data. There
were no language restrictions.
Eligibility criteria
Eligibility criteria were any test accuracy study where the
detection of HPVDNA in urine was compared with its detection
in the cervix in any sexually active woman concerned about
HPV infection or the development of cervical cancer. We
excluded studies if a different or no reference standard was used.
We included studies in the meta-analysis if 2×2 tables could be
constructed from published or requested data. Certain factors
can overestimate the diagnostic value of a test.16 Therefore we
excluded studies from themeta-analysis if they used case-control
designs, tested only patients with cervical cancer, or the total
number of non-infected participants was zero.
Study selection and data extraction
We screened all titles and abstracts for relevant studies. Two
reviewers (NP and JD) independently reviewed full texts for
final selection. They documented reasons for exclusion.
We developed a data extraction sheet, piloted it on randomly
selected studies, and refined it appropriately. Two reviewers
(NP and JD) extracted the following data independently: study
characteristics (authors, year of publication, country, context
and purpose of testing), patient characteristics (including mean
age and range, HIV status, cytology and biopsy results),
characteristics of the index test (urine sample type, sample
volume, storage temperature, DNA extraction method, DNA
amplification method, timing of test in relation to reference
standard), and accuracy of results into 2×2 tables of urine
positivity versus cervical swab positivity for any HPV, high
risk HPV, and HPV 16 and 18. We considered the following
HPV strains to be high risk: 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68, 73, and 82.We emailed study authors for missing
data.
We discussed all discrepancies and involved a third independent
reviewer (KK) if the discrepancy could not be resolved.
Assessment of study quality
We applied the QUADAS-2 tool to all studies.17 Quality
assessment involved scrutinising patient selection, conduct of
the index test, conduct of the reference standard, and patient
flow. We considered a study to be high quality if it used an
appropriate patient spectrum, it used consecutive or random
recruitment of participants, all participants used the same
reference standard, the index and reference standard were
performed within two weeks, and the majority of recruited
participants were included in analyses.
The following were considered to be inappropriate patient
spectrums that introduced bias as a result of a higher prevalence
of HPV: populations comprising only patients with HIV, cervical
cancer, or high grade CIN, or whose age was below current
screening recommendations. We did not consider lack of
blinding to test results as posing a high risk of bias, as the HPV
test is objective. We assessed publication bias by regressing
log(DOR) on inverse root squared of the effective sample size.
However, this result should be interpreted cautiously given the
lack of statistical power of this test and the absence of consensus
on adequate methods to detect publication bias.15 18
Data synthesis
Data synthesis was performed according to a priori hypotheses
outlined in the protocol.We constructed 2×2 tables of detection
of any HPV, high risk HPV, and HPV 16 and 18. For these three
groups we fitted bivariate mixed effects logistic regression
analysis. From the estimates we derived a summary receiver
operating characteristic curve and the following summary
accuracy measures with 95% confidence intervals: sensitivity
(true positive rate), test specificity (true negative rate), positive
likelihood ratio, and negative likelihood ratio. Where studies
used more than one method of urine HPV testing, we included
the method that was most similar to that of other studies in this
review.
To visually explore heterogeneity, we generated forest plots for
test sensitivity (true positive rate) and test specificity (true
negative rate) with 95% confidence intervals for individual
studies. To investigate sources of heterogeneity for both
sensitivity and specificity, we included in the bivariate mixed
effects models the following planned covariates: purpose of
testing (HPV surveillance versus cervical cancer screening and
follow-up of CIN), mean age, HIV status (positive versus
negative for antibodies to HIV), prevalence of low grade or
worse intraepithelial lesions on cytology, prevalence of grade
2 or worse CIN on biopsy, urine sampling method (first void
urine versus random and midstream urine), HPV detection
method (real time polymerase chain reaction (PCR) and nested
PCR versus conventional PCR), use of non-commercial versus
commercial DNA extraction methods, use of non-commercial
versus commercial DNA amplificationmethods, and low versus
high risk of bias as a result of patient selection. Owing to the
restricted number of studies, we entered only one covariate in
each analysis. We also did a sensitivity analysis to investigate
the effect of studies including a narrow patient spectrum.
Statistical analyses were performed using themetandi andmidas
functions in STATA (version 13.0), and using METADAS
macro in SAS (version 9.3).
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Results
Figure 1⇓ summarises the identification and selection of studies.
Of the 1373 potential records, 23 articles reporting on 21 studies
(2277 sexually active women) were included in the systematic
review.10 19-40 Of these, 16 articles reporting on 14 studies (1535
women recruited, 1443 women analysed) were included in the
meta-analysis.19-22 24 27-31 34-39
Description of studies
Supplementary appendix 1 details the characteristics of
individual studies. Twelve out of 21 study populations were
recruited from gynaecology or colposcopy outpatient clinics
and seven from genitourinary medicine or HIV clinics. For most
study populations the purpose of testing was for cervical cancer
screening (15/21). The remainder were for HPV surveillance
(5/21) or follow-up of CIN (1/21). Four out of the 21 populations
were positive for HIV. Of the 11 populations with reported
cytology results, 35.9% (304/847) of women had low grade
dysplasia or worse. Of the 10 populations with reported biopsy
results, 54.1% (385/712) of women had grade 2 or worse CIN
and 17.0% (121/712) had biopsy proved cervical cancer. Most
of the studies used conventional PCR (18/21), but testing
methods were not uniform. Two of the 21 studies used nested
PCR and one out of the 21 used PCR based DNAmicroarray.32-34
Three studies evaluated quantitative real time PCR and hybrid
capture in addition to conventional PCR.10 23 36 In these cases,
only the results for conventional PCR were included in the
meta-analysis. The majority of urine sampling was first void
(12/21). Other sampling methods included random (2/21),
midstream (2/21), morning (1/21), and not specified (4/21).
Urine storage temperature ranged from −70°C to 4°C. Sixteen
studies used commercial DNA extraction kits and 11 used
commercial amplification platforms. The remainder used
in-house methods. The reference standard in all studies was a
cervical sample taken by a clinician to test for HPV DNA.
Quality of studies
Figure 2⇓ outlines the quality assessment of studies included
in the meta-analysis. All included studies avoided case-control
designs and most studies (9/14) used consecutive or random
recruitment of participants. Six studies had a high risk of bias
for patient selection owing to narrow patient spectrums: four
articles reported on three studies of only patients with
HIV,27 28 35 39 two studies reported on only adolescents,21 36 and
one study reported on only patients with high grade CIN.24 All
studies had a low risk of bias owing to patient flow and timing;
13/14 analysed all recruited participants and one analysed 94%
of recruited participants. There was an appropriate interval
between tests, with 8/14 studies completing both tests on the
same day and urine samples being taken before cervical samples.
All studies had a low risk of bias for the conduct of the reference
standard. Five of the 14 studies used in-house methods for the
index test and did not specify a threshold. These were rated as
having an unclear risk of bias. The remainder was rated as low
risk of bias as they used a prespecified index test threshold
(9/14). Only one study reported blinding to test results,37
although DNA testing is objective and should not result in bias.
Regarding applicability of studies to the review questions, there
were no concerns about the index test or reference standard.
Most studies (19/21) were rated as low concern of applicability
for patient selection to the review question. The two rated as
having high concerns were studies of adolescents only, because
they included patients who would not normally be screened.21 36
We found no significant asymmetry in the funnel plot (P=0.62)
and hence no evidence of publication bias.
Meta-analysis
Supplementary appendix 2(a-c) illustrates the variation in
sensitivity and specificity between individual studies for urine
detection of any HPV (14 studies), high risk HPV (11 studies),
and HPV 16 and 18 (11 studies). For urine detection of any
HPV, individual sensitivities ranged from 53%19 to 99%35 and
specificities from 38%27 to 99%.31 For urine detection of high
risk HPV, individual sensitivities ranged from 50%19 to 98%30
and specificities from 17%35 to 99%.22 For urine detection of
HPV 16 and 18, individual sensitivities ranged from 23%20 to
97%30 and specificities from 56%28 39 to 99%.31
Figure 3⇓ summarises the pooled sensitivity and specificities
as summary receiver operating curves for the same three groups.
Urine detection of any HPV had a pooled sensitivity of 87%
(95% confidence interval 78% to 92%) and specificity of 94%
(95% confidence interval 82% to 98%). Urine detection of high
risk HPV had a pooled sensitivity of 77% (68% to 84%) and
specificity of 88% (58% to 97%). Urine detection of HPV 16
and 18 had a pooled sensitivity of 73% (56% to 86%) and
specificity of 98% (91% to 100%). The 95% prediction regions
consistently occupy the whole upper left quadrant of the receiver
operating characteristic plots in figure 3. This demonstrates high
heterogeneity between studies. For detection of HPV 16 and
18, the 95% prediction region has the most heterogeneity,
occupying most of the plot in figure 3. Between study variance
in specificity (6.0, 95% confidence interval 1.8 to 19.7) was
higher when detecting high risk HPV compared with variance
in sensitivity (0.4, 95% confidence interval 0.1 to 2.2, fig 3).
For detection of any HPV, the positive likelihood ratio was
15.22 (95% confidence interval 4.56 to 50.81) and the negative
likelihood ratio was 0.14 (95% confidence interval 0.10 to 0.20).
For detection of high risk HPV, the positive likelihood ratio
was 6.33 (1.48 to 27.00) and the negative likelihood ratio was
0.26 (0.16 to 0.41). For detection of HPV 16 and 18, the positive
likelihood ratio was 36.97 (6.77 to 201.91) and the negative
likelihood ratio was 0.27 (0.15 to 0.49).
Sources of heterogeneity
The table⇓ summarises the results of the bivariate
metaregression based on planned covariates. There was a 22-fold
increase in overall accuracy when samples were collected as
first void urine compared with random or midstream urine
samples (relative diagnostic odds ratio 21.7, 95% confidence
interval 1.3 to 376). However, this difference in accuracy is
exclusively based on a significant increase in sensitivity of first
void urine (relative sensitivity 1.2, 95% confidence interval 1.06
to 1.37, P=0.004). Specificity was not affected by the urine
sampling method (P=0.46). Purpose of testing, mean age of
participants, HIV status, cytology and biopsy results, detection
methods, use of commercial methods, or risk of bias as a result
of patient selection did not explain any heterogeneity between
indices for study accuracy.
Sensitivity analysis
Pooled sensitivity and specificity for detection of any HPV in
urine was similar when studies with a narrow spectrum of
patients were excluded.21 24 27 28 35 36 39 Sensitivity was 80% (95%
confidence interval 71% to 88%) and specificity was 98% (95%
confidence interval 89% to 100%).
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Discussion
Our review shows that detection of human papillomavirus (HPV)
DNA in urine has a good accuracy for the presence of cervical
HPV. Sensitivity was moderate for detection of any HPV, high
risk HPV, and HPV 16 and 18. The specificity for detection of
HPV in urine was especially high for any HPV and the most
oncogenic strains, HPV 16 and 18.
Strengths and weaknesses of this study
The strength of this review lies in the methodology used. We
followed guidelines for the conduct and reporting of systematic
reviews to ensure high quality selection of studies and data
extraction of data.14 15 17 We undertook an extensive literature
search using all relevant electronic databases, and we manually
searched through references and journals. Two reviewers
independently reviewed all titles, abstracts, and full texts, and
extracted data, with no restriction on language.
Our meta-analysis included 14 studies and a large sample of
women. The quality of included studies was generally high. The
main deficiency in included studies was the use of narrow patient
spectrums in six studies including only participants with HIV,
adolescents, or participants with high grade cervical
intraepithelial neoplasia (CIN).21 24 27 28 35 36 39 These factors lead
towards a high prevalence and could result in biased estimation
of test accuracy.16 41 However, metaregression analysis did not
reveal any variation in accuracy when we used HIV status, mean
age, and biopsy results as covariates. Although we could not
perform a multivariable metaregression analysis owing to the
limited number of studies available, a sensitivity analysis
excluding the six studies with narrow patient spectrums had
little impact on point estimates of pooled accuracy measures.
Although most of the studies used conventional polymerase
chain reaction (PCR), allowing us to pool results, we did identify
heterogeneity in testing methods. Studies were conducted in
diverse settings, including primary and secondary care, with
different HPV testing platforms and conditions. One previous
review states that such heterogeneity makes pooled sensitivities
and specificities redundant.11However, we argue that confirming
a high accuracy, despite variations in testing methods, makes
the test worthy of further investigation and standardisation. We
also performed a metaregression to identify whether this
variation in testing methods affected results. Only urine
sampling was identified as a source of heterogeneity, with a
22-fold reduction in accuracy when samples were collected as
random or midstream samples rather than as first void. This is
an important and expected finding as first void urine samples
contain higher levels of DNA making them more amenable to
PCR. They are the sample of choice for viral DNA detection,
and our findings show that they should be the sample of choice
for urine HPV detection.42
A major limitation of this meta-analysis is the between study
variation in pooled sensitivities and specificities, which are
evident in figure 3. This means that all results must be
interpreted with caution as they may have been overestimated
or underestimated.
Comparison with existing literature
Three reviews have been published on the detection of HPV
DNA in urine. The first concluded that urine HPV detection
was worse than cervical HPV detection at predicting CIN.43 The
second focused on surveillance in adolescents rather than in
women at an age to be included in cervical cancer screening
programmes.12 The third appraised the potential importance of
variations in urine sampling, storage, and testing methods.11 The
latter two reviews concluded that urine HPV detection could be
an adequate tool in women, but none of the three reviews
included a meta-analysis to support their conclusions.
Our review provides meta-analysis and metaregression
demonstrating the accuracy of detection of HPV in urine for the
presence of cervical HPV. We also update the literature by
reporting on four additional studies (476 women) published
since previous reviews.28 35 37 39 44 We agree with previous
reviews that heterogeneous methods of urine testing affect the
interpretation of pooled accuracy measures and that a uniform
method for detection of HPV in urine must be developed.
However, by providing quantitative evidence of accuracy in
urine HPV detection and establishing that urine sampling affects
accuracy, our review can drive the prioritisation of efforts to
standardise urine HPV testing.
Implications for clinical practice and future
research
The detection of HPV in urine is non-invasive, easily accessible,
and acceptable to women,10 and a test with these qualities could
considerably increase uptake. Urine based testing has been
successful for the detection of common sexually transmitted
infections, including Chlamydia trachomatis and Neisseria
gonorrhoea.45 We have shown that testing urine for HPV could
accurately replace cervical testing for HPV in this context. In
particular, the high specificity and the large positive likelihood
ratio provoke important changes in the likelihood of infection
for a woman with a positive test result. Our review predicts that
positive test results are 15 times more likely to occur in infected
women than in non-infected women. This is a major strength
of the testing method, as false positive results would lead to
women undergoing unnecessary invasive investigations,
including cytology, colposcopy, or biopsy, to prove lack of
disease. This would generate increased anxiety and costs, which
could be reduced by urine based testing. The high specificity
of this test makes this scenario less likely and could thereby
increase trust and uptake.
However, our results must be interpreted with caution for several
reasons. Firstly, sensitivity was not as high as specificity and
negative test results are only seven times more likely to occur
in non-infected women than in infected women. Secondly, there
was wide variation in accuracy between individual studies, and
pooled sensitivities and specificities may have been
overestimated or underestimated. The consequences of
overestimation are especially important as they can lead to
unacceptable morbidity and mortality. False negative results
would lead to missing cases of precancerous or cancerous
lesions, and false positive results would lead to
over-investigation and anxiety. Both scenarios could easily
result in a lack of trust in HPV testing. To confidently adopt the
test into current practice, test methods must be more consistent
and reproducible. As the consequences of false negative results
are serious (missing cervical precancer and cancer), the test
could be done more frequently than current screening methods.
This would improve the chances of minimising false negative
results. Our metaregression identified that the current variation
between study results is partly explained by different urine
sampling techniques. No other explanations of heterogeneity
were identified by our metaregression, including analysis of the
method for HPV detection and commercial versus
non-commercial extraction and amplificationmethods. However,
these analyses are based on a limited number of studies and
therefore we cannot exclude the presence of other associations.
We therefore recommend the standardisation of methods for
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urine testing to minimise variation before incorporating urinary
detection of HPV into guidelines for cervical cancer screening.
The World Health Organization HPV Laboratory Network is
active in this domain, and our results should drive further
prioritization of urine testing.46
Finally, our review focused on the accuracy of detecting HPV
in the cervix, so that where cervical testing for HPV is being
considered for guidelines on cervical cancer screening, urine
based testing can be considered instead. Published guidance on
recommending diagnostic tests emphasises that test accuracy
is only a surrogate measure for patient important outcomes,
which must also be considered before adopting a screening
method.47 In the case of cervical cancer screening, patient
important outcomes that must be considered include
acceptability of testing, prediction of CIN or invasive cancer,
management of positive test results, and safe intervals for testing
between negative test results. Although acceptability of urine
HPV testing has already been shown in published literature,10
the remaining outcomes have not. We were unable to do a
meta-analysis on accuracy of CIN prediction as too few studies
report adequate data. Two studies included in our meta-analysis
reported relevant data. The first had a sensitivity of 62.7% and
a specificity of 47.1%37 and the second study a sensitivity of
80.8%.24 We were unable to calculate a valid estimation of
specificity for the second study, as no participants were infected
with HPV. Future test accuracy studies must report paired results
for detection of HPV in urine and cytology or biopsy outcomes
so that this can be meta-analysed. To our knowledge, pathways
for the management of positive and negative test results have
not been reported in the literature. New studies on the detection
of HPV in urine must assess the feasibility and costs of these
pathways.48
Conclusions
Our review demonstrates the accuracy of detection of HPV in
urine for the presence of cervical HPV. When cervical testing
for HPV is sought, urine based testing should be an acceptable
alternative to increase coverage for subgroups that are hard to
reach. However, results must be interpreted with caution owing
to variation between individual studies for participant
characteristics, lack of standardised methods of urine testing,
and the surrogate nature of cervical HPV for cervical disease.
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Table
Table 1| Bivariate metaregression of study characteristics on sensitivity and specificity for detection of human papillomavirus (HPV) in
urine compared with cervical detection
Diagnostic odds ratio
(95% CI), P value
Specificity (95% CI), P
value
Sensitivity (95% CI), P
valueCategories (sample size)P value*
No of
studiesCovariate
264 (76 to 914); 12.2 (0.9,
159), 0.0345
97.0 (94.1 to 98.5); 81.1
(25.9 to 98.1), 0.4593
89.0 (75.3 to 95.5); 73.9
(68.3 to 78.8), 0.0042
First void urine(n=8); random
or midstream urine (n=4)
0.00412Urine sampling
49 (8 to 311); 162 (29 to
915), 0.3427
81.5 (52.6 to 94.6); 97.4
(90.0 to 99.4), 0.1696
91.8 (82.1 to 96.5); 81.3
(68.3 to 89.8), 0.1104
High risk (n=6); low risk (n=8)0.03614Bias in patient
selection
172 (11 to 2569); 82 (15 to
454)
95.3 (59.4 to 99.6); 93.9
(76.9 to 98.6)
89.7 (80.6 to 94.8); 84.2
(71.8 to 91.8)
HPV surveillance (n=5);
cervical cancer screening or
CIN follow-up (n=9)
0.70814Purpose
42 (3 to 571); 175 (31 to
1000)
71.7 (34.0 to 92.6); 97.0
(86.9 to 99.4)
94.3 (71.9 to 99.1); 84.5
(75.3 to 90.7)
Positive (n=3); negative (n=11)0.09914HIV status
131 (26 to 657); 52 (2 to
1259)
95.2 (82.1 to 98.8); 90.0
(35.1 to 99.3)
86.9 ( 77.3 to 92.8); 85.3
(57.8 to 96.1)
Conventional PCR (n=12); real
time and nested PCR (n=2)
0.96614HPV detection
method
163 (3 to 8528); 123 (22 to
680)
96.4 (43.3 to 99.9); 94.7
(79.2 to 98.8)






28 (5 to 156); 275 (50 to
1522)
81.9 (51.3 to 95.1); 97.6
(89.8 to 99.5)






CIN=cervical intraepithelial neoplasia; PCR=polymerase chain reaction.
*Likelihood ratio test.
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Figures
Fig 1 Study selection process
Fig 2 QUADAS-2 quality assessment of 14 studies included in meta-analysis
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g5264 doi: 10.1136/bmj.g5264 (Published 16 September 2014) Page 8 of 9
RESEARCH
Fig 3 Receiver operating characteristic plots for studies evaluating accuracy of detecting human papillomavirus (HPV) in
urine compared with in cervix
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